Promise and peril in wellness neurotech
We reviewed more than a hundred wellness neurotechnology company websites — examining their marketing claims, the evidence behind them, and what they do or don't disclose about regulatory status.
The rapid growth of wellness neurotechnologies is revealing a regulatory grey zone between medical and consumer markets. These devices operate at the intersection of strong commercial incentives, pressing public health needs, and regulatory frameworks designed for a time when the boundary between medical and consumer products was far clearer. In this series of articles, CFG examines that tension from multiple perspectives, concluding with a proposal for how regulators can respond to support ethical innovation.
We reviewed more than a hundred wellness neurotechnology company websites — examining their marketing claims, the evidence behind them, and what they do or don't disclose about regulatory status.
Consumer neurotechnology devices are multiplying fast — and slipping through the gap between medical regulation and the consumer market. CFG examines the tensions driving this grey zone, and what regulators can do about it.